Product image of Meliglix 25 Mg (Sitagliptin Hydrochloride) supplied by GNH India

Meliglix 25 Mg

Active Ingredient:
Sitagliptin Hydrochloride
Origin:
EU

Meliglix 25 Mg (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Meliglix 25 Mg, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a 25 mg tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving glycaemic control when combined with diet and exercise.

GNH India supplies Meliglix 25 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meliglix (sitagliptin) is used within the antidiabetic drug class to manage blood glucose levels in type 2 diabetes.

  • Type 2 diabetes mellitus: lowers HbA1c and fasting plasma glucose when added to diet and exercise.
  • Monotherapy in type 2 diabetes: provides glucose‑dependent insulin secretion without causing hypoglycaemia.
  • Combination therapy with metformin: enhances overall glycaemic control in patients inadequately controlled on metformin alone.

How It Works

  • Sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this breakdown, sitagliptin increases circulating levels of GLP‑1 and GIP, leading to glucose‑dependent enhancement of insulin secretion from pancreatic β‑cells and suppression of glucagon release from α‑cells, thereby reducing blood glucose concentrations.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nasal passages and throat.
  • Headache: transient mild to moderate head pain.
  • Upper respiratory tract infection: symptoms such as cough and congestion.
  • Nausea: occasional stomach upset.
  • Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: including anaphylaxis, Stevens‑Johnson syndrome, or angioedema.
  • Severe joint pain: unexplained arthralgia that may be disabling.
  • Bullous pemphigoid: rare skin blistering disorder.
  • Hepatic injury: abnormal liver function tests or hepatitis.

Precautions & Warnings

Before initiating therapy, consider the following safety measures.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: use with caution in patients with liver disease.
  • Pancreatitis risk: discontinue if persistent severe abdominal pain occurs.
  • Hypersensitivity: stop treatment if signs of severe allergic reaction develop.
  • Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Avoid Interactions

Sitagliptin may interact with other medicines; monitor accordingly.

Major Interactions (Avoid)

  • Concomitant insulin: increased risk of hypoglycaemia; dose adjustments required.
  • Sulfonylureas: may potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely)

  • Rifampin: reduces sitagliptin exposure, may diminish efficacy.
  • Digoxin: may increase digoxin serum concentrations.
  • Warfarin: potential alteration of INR, monitor coagulation parameters.
  • NSAIDs: may affect renal function, especially in patients with pre‑existing kidney disease.

Frequently Asked Questions

Meliglix 25 Mg contains sitagliptin hydrochloride, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when combined with diet, exercise, and other antidiabetic agents as prescribed by a healthcare professional.

Sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels without causing significant hypoglycaemia.

The dosage of Meliglix 25 Mg is determined by the prescribing clinician based on the individual’s medical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety of sitagliptin during pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or insulin. DPP‑4 inhibitors provide glucose‑dependent insulin release with a low risk of hypoglycaemia and are often used as add‑on therapy when metformin alone does not achieve target glycaemic control.

Store Meliglix 25 Mg tablets at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Meliglix is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients must follow the dosing schedule prescribed by their healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and rare cases of severe joint pain or bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or joint discomfort.

Meliglix should be avoided in individuals with known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised for patients with severe renal or hepatic impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless deemed necessary by a physician.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT